MedTrace Logo

Dexamfetamine Sulphate in Patients With Glioma Suffering From Severe Asthenia

NCT02363075 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2016-09-15

No results posted yet for this study

Summary

The main purpose of this study is to estimate the efficiency at 3 months of dexamfetamine sulphate on the MFI 20 scale in severe fatigue of patients with stabilized gliomas.

Conditions

Interventions

DRUG

Dexamfetamine sulphate

10mg/day per os for the first ten days, 20mg/day for the ten following days, 30mg/day until D90.

DRUG

placebo

10mg/day per os for the first ten days, 20mg/day for the ten following days, 30mg/day until D90.

Sponsors & Collaborators

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Florence LAIGLE-DONADEY, MD · Assistance Publique - Hôpitaux de Paris

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2017-07-31
Completion
2018-01-31

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02363075 on ClinicalTrials.gov